Disclosures for "Lymphocyte Reconstitution Patterns in People with MS Being Treated with Rituximab After Alemtuzumab to Reduce the Frequency of Autoimmune Adverse Events in the RAMBLE Trial"
-
Miss Jimenez Sanchez has received research support from Multiple Sclerosis Australia .
-
The institution of Dr. Broadley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Broadley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. The institution of Dr. Broadley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Broadley has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Broadley has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Broadley has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage. The institution of Dr. Broadley has received research support from NHMRC. The institution of Dr. Broadley has received research support from ARC. The institution of Dr. Broadley has received research support from GCH Foundation. The institution of Dr. Broadley has received research support from NHMRC.
-
Prof. Marshall-Gradisnik has nothing to disclose.
-
Dr. Eaton-Fitch has nothing to disclose.